Home Featured Page 12

Featured

Latest

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

High Hopes in the Mile High City: Inside Colorado’s First Licensed Psilocybin Center

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Oakland Psychedelic Conference

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

Backed by $15m in NIDA Funding, NYU and B.More Team Up...

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of...

Philosophy and Psychedelics: Can Metaphysics Bring Meaning to Non-Ordinary States?

The Business of Psychedelics with Joe Moore and Jaime Fiorucci

Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape...

The Penn Psychedelics Collaborative and the Power of Interdisciplinary Connections

Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely...

Natural Medicine Advisory Bulletin 14

1...111213...285 Page 12 of 285

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

High Hopes in the Mile High City: Inside Colorado’s First Licensed Psilocybin Center

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Psychedelic Science 2025

Oakland Psychedelic Conference

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

Backed by $15m in NIDA Funding, NYU and B.More Team Up...

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of...

Philosophy and Psychedelics: Can Metaphysics Bring Meaning to Non-Ordinary States?

The Business of Psychedelics with Joe Moore and Jaime Fiorucci

Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape...

The Penn Psychedelics Collaborative and the Power of Interdisciplinary Connections

Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely...

Natural Medicine Advisory Bulletin 14

EDITOR PICKS

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY